opzelura
(ruxolitinib)Incyte Corporation
Usage: OPZELURA is indicated for the topical short-term treatment of mild to moderate atopic dermatitis in patients 12 years and older, and for nonsegmental vitiligo in adults and pediatric patients. It should not be used in combination with other JAK inhibitors or potent immunosuppressants.